Skip to main navigation Skip to search Skip to main content

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

  • Yoshihiko Sakata
  • , Shinya Sakata
  • , Yuko Oya
  • , Motohiro Tamiya
  • , Hidekazu Suzuki
  • , Ryota Shibaki
  • , Asuka Okada
  • , Hiroshi Kobe
  • , Hirotaka Matsumoto
  • , Takashi Yokoi
  • , Yuki Sato
  • , Takeshi Uenami
  • , Go Saito
  • , Yoko Tsukita
  • , Megumi Inaba
  • , Hideki Ikeda
  • , Daisuke Arai
  • , Hirotaka Maruyama
  • , Satoshi Hara
  • , Shinsuke Tsumura
    • Jun Morinaga, Takuro Sakagami

Research output: Contribution to journal › Article › peer-review

90   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry